REV-ERB regulates RORγt+ regulatory T cell specification and function through the Bhlhe40-c-Maf axis
Journal of Experimental Medicine · 2026
DOI: 10.1084/jem.20241463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Xianting Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Eye and ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Proto-Oncogene Proteins c-maf, T-Lymphocytes, Regulatory, Basic Helix-Loop-Helix Proteins. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Natural Science Foundation of China.
Abstract (Originalsprache)
Foxp3+ regulatory T (Treg) cells co-expressing RORγt adopt specialized functions to restrain intestinal inflammation. However, despite extensive characterization, the factors governing RORγt+Foxp3+ Treg specialization remain unclear. Here, we report that transcriptional repressor REV-ERB is critical for the differentiation and function of colonic RORγt+Foxp3+ Treg cells. REV-ERB deficiency exacerbates both TNBS- and oxazolone-induced intestinal inflammation. Mechanistically, REV-ERB promotes RORγt expression through suppressing the expression of transcriptional repressor Bhlhe40, which in turn inhibits c-Maf, a key factor promoting colonic RORγt+Foxp3+ Treg differentiation and function. Moreover, this Bhlhe40-c-Maf axis downstream of REV-ERB also regulates the expression of core colonic Treg signature genes including IL-10 and CTLA-4, while REV-ERB additionally safeguards RORγt+Foxp3+ Treg functional stability by directly suppressing proinflammatory cytokine IL-17A production. Collectively, the present study identifies that REV-ERB along with the downstream Bhlhe40-c-Maf axis jointly controls the RORγt+Foxp3+ Treg differentiation and suppressive function, suggesting that modulating their activities may strengthen RORγt+Foxp3+ Treg function to ameliorate inflammatory bowel diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Head and Neck Surgery, Eye and ENT Hospital, Fudan University, Shanghai, China.
- NOMIS Center for Immunology and Microbial Pathogenesis, Salk Institute for Biological Studies , La Jolla, CA, USA.
- Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.
- Razavi Newman Integrative Genomics and Bioinformatics Core, Salk Institute for Biological Studies , La Jolla, CA, USA.
- Wake Forest Baptist Health , Winston-Salem, NC, USA.
ORCID-Profile: Xianting Hu, Zhi Liu, Yao Li, Yannan You, Kaiye Yue, Yuqiong Liang, Chin-San Loo, Jingting Yu, Matthias Leblanc, Dehui Wang, Huabin Li, Ye Zheng
Förderung
- NIH HHS
- NCI NIH HHS
- National Natural Science Foundation of China
- NOMIS Foundation
- NIA NIH HHS
- Sol Goldman Charitable Trust
- Salk Institute
- Noncommunicable Chronic Diseases-National Science and Technology
Zitieren
APA
Hu, X., Liu, Z., Li, Y., You, Y., Yue, K., Liang, Y., Loo, C. S., Yu, J., Leblanc, M., Wang, D., Li, H., & Zheng, Y. (2026). REV-ERB regulates RORγt+ regulatory T cell specification and function through the Bhlhe40-c-Maf axis. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20241463
Vancouver
Hu X, Liu Z, Li Y, You Y, Yue K, Liang Y, et al. REV-ERB regulates RORγt+ regulatory T cell specification and function through the Bhlhe40-c-Maf axis. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20241463
BibTeX
@article{Hu2026,
author = {Hu, Xianting and Liu, Zhi and Li, Yao and You, Yannan and Yue, Kaiye and Liang, Yuqiong and Loo, Chin-San and Yu, Jingting and Leblanc, Matthias and Wang, Dehui and Li, Huabin and Zheng, Ye},
title = {REV-ERB regulates RORγt+ regulatory T cell specification and function through the Bhlhe40-c-Maf axis},
journal = {Journal of Experimental Medicine},
year = {2026},
doi = {10.1084/jem.20241463}
}
EUVIMED